(a) To determine both the frequency of injecting inside prison and use of sterilising tablets to clean needles in the previous four weeks ; (b) to assess the efficiency of random mandatory drugs testing at detecting prisoners who inject heroin inside prison ; (c) to determine the percentage of prisoners who had been offered vaccination against hepatitis B. Design :
(a) To determine both the frequency of injecting inside prison and use of sterilising tablets to clean needles in the previous four weeks ;
(b) to assess the efficiency of random mandatory drugs testing at detecting prisoners who inject heroin inside prison ;
Cross sectional willing anonymous salivary HIV surveillance linked to a self completion risk factor questionnaire.
Lowmoss prison, Glasgow, and Aberdeen prison on 11 and 30 October 1996.
293 (94%) of all 312 inmates at Lowmoss and 146 (93%) of all 157 at Aberdeen, resulting in 286 and 143 valid questionnaires.
Frequency of injecting inside prison in the previous four weeks by injector inmates who had been in prison for at least four weeks.
116 (41%) Lowmoss and 53 (37%) Aberdeen prisoners had a history of injecting drug use but only 4% of inmates (17/395 ; 95% confidence interval 2% to 6%) had ever been offered vaccination against hepatitis B. 42 Lowmoss prisoners (estimated 207 injections and 258 uses of sterilising tablets) and 31 Aberdeen prisoners (229 injections, 221 uses) had injected inside prison in the previous four weeks. (...)
Mots-clés Pascal : Milieu carcéral, Etude transversale, Enquête sur terrain, Comprimé, Stérilisé, Injection, Etude comparative, Evaluation, Nuisance, Hépatite virale B, Virose, Infection, Virus immunodéficience humaine, Lentivirinae, Retroviridae, Virus, Facteur risque, Homme, Système nerveux pathologie, Psychopathologie, Chimiothérapie, Immunoprophylaxie, Appareil digestif pathologie, Foie pathologie
Mots-clés Pascal anglais : Carceral environment, Cross sectional study, Field inquiry, Tablet, Sterilized, Injection, Comparative study, Evaluation, Nuisance, Viral hepatitis B, Viral disease, Infection, Human immunodeficiency virus, Lentivirinae, Retroviridae, Virus, Risk factor, Human, Nervous system diseases, Psychopathology, Chemotherapy, Immunoprophylaxis, Digestive diseases, Hepatic disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0381226
Code Inist : 002B18C05A. Création : 12/09/1997.